Pfizer, a US pharmacy corporation, has aims to make the coronavirus vaccine available in the US by the end of the current year. The candidate of Pfizer is currently undergoing phase-3 research in the US and is being produced in collaboration with German firm BioNTech. By October end Pfizer want to confirm whether vaccine is safe or not. Bourla echoed this in an interview and said 60% were expected to be able to determine the effectiveness of the vaccine by October. One of the reasons for sparking anticipation of the availability in the US of a vaccine before the presidential elections of 3 November was a previous statement by Pfizer concerning the October efficacy testing plan.
The phase-3 clinical trial is being carried out for Pfizer-BionTech COVID-19 vaccine. An updated guideline was proposed Saturday to the FDA, which extended the registration of their phase-3 vaccine trial to about 44,000 patients-beginning from 30,000 originally expected. The companies reported in a press release that the extension proposal would allow them to further expand trial demographic size to include young teenagers under the age of 16 years to individuals with chronic, persistent HIV, Hepatitis C or Hepatitis B infection. They continue to anticipate a final reading of the effectiveness of the vaccine by the end of October by Pfizer and BionTech. COVID-19 is one of the developers currently undergoing late-stage testing in Pfizer-BionTech. Meanwhile, on Saturday, following a brief pause in global trials last week, Astra Zeneca announced that it would re-launch its phase-3 study for an unknown condition in a female researcher.
Together with German pharmacist BioNTech, the US pharmaceutical giant has worked. In July the US Government said that if it proved effective and efficacious, it will pay corporations US$ 1.95 Bn to manufacture and distribute 100 million doses of its vaccine. The contract was entered into in Operation Super Pace by Trump to promote the production and produce of coronavirus vaccines and treatments.